NovaBay Pharmaceuticals, Inc. Debt/Equity

Debt/Equity of NBY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 30, 2022 was 0.14 (a 7.21% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity increased by 589.95%
  • Annual Debt/Equity for 2021 was 0.05 (a 32.84% increase from previous year)
  • Annual Debt/Equity for 2020 was 0.04 (a -99.02% decrease from previous year)
  • Annual Debt/Equity for 2019 was 4.16 (a Infinity% increase from previous year)
Visit stockrow.com/NBY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of NovaBay Pharmaceuticals, Inc.

Most recent Debt/Equityof NBY including historical data for past 10 years.

Interactive Chart of Debt/Equity of NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.14 0.13
2021 0.05 0.02 0.03 0.04 0.05
2020 0.04 0.05 1.47 -9.7 0.04
2019 4.16 0.48 2.29 2.04 4.16
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 -0.21 -0.42 0.0
2015 -0.32 0.0 0.0 0.0 -0.32
2014 0.0 0.0 0.0 0.0 0.0
2013 0.0 0.0 0.0 0.0 0.0
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0 0.0 0.0

Business Profile of NovaBay Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology